title: Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study.
abstract: OBJECTIVE
  Dyspnoea and pulmonary and/or peripheral congestion are the most frequent manifestations of acute heart failure (AHF) and are important targets for therapy. We have assessed changes in dyspnoea, their relationship with mortality, and the effects of the adenosine A1 receptor antagonist rolofylline on these endpoints in patients enrolled in the PROTECT trial.
  
  
  RESULTS
  PROTECT was a prospective, double-blind, placebo-controlled study assessing the effect of rolofylline in patients hospitalized for AHF with dyspnoea, fluid overload, increased plasma natriuretic peptides, and mild-to-moderate renal dysfunction. Early dyspnoea relief, prospectively defined as moderately or markedly better dyspnoea at both 24 and 48 h after the start of study drug administration, occurred in 49.8% of the patients. Early dyspnoea relief was associated with greater weight loss and with reduced mortality at Days 14 and 30 [hazard ratio (HR) 0.28, 95% confidence interval (CI): 0.15, 0.50; and 0.35, 95% CI: 0.22, 0.55, respectively]. Rolofylline administration was associated with an increase in the proportion of patients showing early dyspnoea relief (HR 1.30; 95% CI: 1.08, 1.57) and with a numerically lower mortality at 14 and 30 days, largely driven by the mortality due to HF [at 30 days, HR (95% CI, P-value): 0.65 (0.38-1.10, P= 0.107)]. Rolofylline did not reduce episodes of in-hospital worsening HF or post-discharge re-admissions, nor did it improve survival at 60 or 180 days.
  
  
  CONCLUSIONS
  The present analysis from PROTECT demonstrated that more weight loss was associated with early dyspnoea relief and reduced short-term mortality.
authors.affiliation: Cardiology, Department of Experimental and Applied Medicine, University of Brescia, Brescia, Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Metra
authors.forename: Christopher M
authors.initials: CM
authors.lastname: O'Connor
authors.forename: Beth A
authors.initials: BA
authors.lastname: Davison
authors.forename: John G F
authors.initials: JG
authors.lastname: Cleland
authors.forename: Piotr
authors.initials: P
authors.lastname: Ponikowski
authors.forename: John R
authors.initials: JR
authors.lastname: Teerlink
authors.forename: Adriaan A
authors.initials: AA
authors.lastname: Voors
authors.forename: Michael M
authors.initials: MM
authors.lastname: Givertz
authors.forename: George A
authors.initials: GA
authors.lastname: Mansoor
authors.forename: Daniel M
authors.initials: DM
authors.lastname: Bloomfield
authors.forename: Gang
authors.initials: G
authors.lastname: Jia
authors.forename: Paul
authors.initials: P
authors.lastname: DeLucca
authors.forename: Barry
authors.initials: B
authors.lastname: Massie
authors.forename: Howard
authors.initials: H
authors.lastname: Dittrich
authors.forename: Gad
authors.initials: G
authors.lastname: Cotter
mesh_terms: D000208:Acute Disease; D058916:Adenosine A1 Receptor Antagonists / Q000008:administration & dosage*; D000368:Aged; D000369:Aged, 80 and over; D004311:Double-Blind Method; D004417:Dyspnea / Q000188:drug therapy* / Q000401:mortality; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality; D006801:Humans; D007262:Infusions, Intravenous; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome; D014970:Xanthines / Q000008:administration & dosage*
chemical_list: D058916:Adenosine A1 Receptor Antagonists; D014970:Xanthines; C073525:rolofylline